Oncology Pharma Inc.
ONPH
$0.0001
$0.000.00%
OTC PK
| 12/31/2004 | 09/30/2004 | 06/30/2004 | 03/31/2004 | 12/31/2003 | |
|---|---|---|---|---|---|
| Revenue | -95.30% | -91.05% | -77.46% | -63.99% | -37.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -95.30% | -91.05% | -77.46% | -63.99% | -37.29% |
| Cost of Revenue | -96.96% | -83.42% | -63.09% | -46.04% | -19.63% |
| Gross Profit | -93.79% | -96.66% | -86.73% | -74.52% | -47.75% |
| SG&A Expenses | -71.02% | -61.87% | -47.37% | -36.42% | -35.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -80.06% | -68.53% | -52.29% | -39.76% | -31.31% |
| Operating Income | 58.33% | 27.17% | 3.73% | -13.10% | 20.50% |
| Income Before Tax | 66.56% | 37.85% | 14.89% | -2.96% | 8.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 66.56% | 37.85% | 14.89% | -2.96% | 8.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 66.56% | 37.85% | 14.89% | -2.96% | 8.67% |
| EBIT | 58.33% | 27.17% | 3.73% | -13.10% | 20.50% |
| EBITDA | 58.92% | 18.91% | -15.95% | -46.08% | 8.44% |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |